|

A Multi-centre Chart Review Study of Stage I-III Non-Small Cell Lung Cancer in China

RECRUITINGSponsored by AstraZeneca
Actively Recruiting
SponsorAstraZeneca
Started2026-04-29
Est. completion2029-04-30
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT07316062

Summary

This chart review study is proposed in China to understand the treatment patterns, biomarker testing, and clinical outcomes with SOC and some selected regimens among patients diagnosed with stage I-III NSCLC.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Stage I-III at initial NSCLC diagnosis
* Aged ≥18 years at first diagnosis of NSCLC
* Timeframe of NSCLC diagnosis:

For DE1: diagnosed with NSCLC during the period between May 1st 2025 and December 31st 2025 For DE2: diagnosed with NSCLC during the period between May 1st 2026 and December 31st 2026 For DE3: diagnosed with NSCLC during the period between May 1st 2027 and December 31st 2027

Exclusion Criteria:

* NSCLC is not the primary cancer diagnosis
* Patients with a recent history of other tumor or concurrent other tumor
* Patients participating in interventional clinical trials at time of initial diagnosis
* Patients with positive pregnancy status at the time of diagnosis

Conditions3

CancerLung CancerNon-Small-Cell Lung

Browse More Trials

Cancer trialsLung Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.